Format

Send to

Choose Destination
Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4.

Immunotherapeutic potential of oncolytic vaccinia virus.

Author information

1
Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1.46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA. ThorneSH@UPMC.edu

Abstract

There has recently been resurgence in interest for the use of replication-selective (oncolytic) viruses for the treatment of cancers. This has been fueled by positive clinical data and the promise provided by next-generation vectors that are better targeted and display enhanced therapeutic potential. One factor that has led to more effective oncolytic vectors has been a greater appreciation of their immunotherapeutic potential. This is especially true for strains of vaccinia virus, where the capability for rapid and destructive spread through a target tissue makes this virus the ideal backbone for an oncolytic agent, while its known ability to produce a potent immune response makes it a powerful immunotherapeutic. Approaches to developing next-generation vectors that are capable of effectively harnessing both of these mechanisms of action are discussed here.

PMID:
21717084
DOI:
10.1007/s12026-011-8211-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center